Your browser is no longer supported. Please, upgrade your browser.
Settings
VIR Vir Biotechnology, Inc. daily Stock Chart
VIR [NASD]
Vir Biotechnology, Inc.
Index- P/E- EPS (ttm)-5.76 Insider Own10.30% Shs Outstand110.78M Perf Week0.82%
Market Cap3.27B Forward P/E- EPS next Y-2.04 Insider Trans0.00% Shs Float100.45M Perf Month-12.64%
Income-174.70M PEG- EPS next Q-0.53 Inst Own63.40% Short Float1.54% Perf Quarter133.39%
Sales8.10M P/S403.46 EPS this Y-443.30% Inst Trans0.07% Short Ratio1.63 Perf Half Y-
Book/sh31.55 P/B0.94 EPS next Y3.30% ROA- Target Price33.33 Perf Year-
Cash/sh3.46 P/C8.52 EPS next 5Y- ROE- 52W Range11.65 - 75.00 Perf YTD134.59%
Dividend- P/FCF- EPS past 5Y- ROI-41.90% 52W High-60.67% Beta-
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low153.21% ATR6.28
Employees229 Current Ratio6.80 Sales Q/Q-65.50% Oper. Margin- RSI (14)46.36 Volatility13.95% 19.06%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.99 Prev Close29.10
ShortableYes LT Debt/Eq0.00 EarningsMar 24 Payout- Avg Volume947.03K Price29.50
Recom3.20 SMA20-19.30% SMA50-6.25% SMA20040.55% Volume1,884,307 Change1.37%
Mar-19-20Downgrade JP Morgan Neutral → Underweight $26
Mar-13-20Downgrade Goldman Buy → Neutral
Feb-27-20Downgrade Robert W. Baird Neutral → Underperform $17
Feb-04-20Downgrade JP Morgan Overweight → Neutral $25 → $26
Nov-14-19Initiated Robert W. Baird Neutral
Nov-05-19Initiated JP Morgan Overweight $25
Nov-05-19Initiated Goldman Buy $37
Nov-05-19Initiated Cowen Outperform
Nov-05-19Initiated Barclays Overweight $25
Apr-08-20 10:05AM  Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More Zacks -9.32%
07:00AM  Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 GlobeNewswire
Apr-07-20 11:00AM  Glaxo to Buy Stake in Vir Biotech, Signs Coronavirus Deal Zacks -12.56%
Apr-06-20 04:03PM  GlaxoSmithKline, Vir Biotech Team Up in Hunt For Coronavirus Treatment SmarterAnalyst +26.55%
09:56AM  GSK to partner with Vir for potential COVID-19 treatments, invest $250 million Reuters
08:12AM  GSK to partner with Vir for potential COVID-19 treatments, invest $250 million Reuters
08:01AM  GSK and Vir Biotechnology enter collaboration to find coronavirus solutions GlobeNewswire
Mar-30-20 07:00AM  Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19 Business Wire
Mar-26-20 04:01PM  Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
10:52AM  Biotech Stocks Accelerate Efforts for Coronavirus Treatments Zacks
10:09AM  3 Biotech Stocks to Watch as the Race for a Coronavirus Vaccine Continues TipRanks
08:23AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger Benzinga
Mar-25-20 08:00AM  Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 GlobeNewswire -6.11%
Mar-18-20 05:49PM  Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More Zacks
Mar-17-20 02:26PM  Cost of inpatient coronavirus treatment could top $20k, study reveals Yahoo Finance Video +9.83%
Mar-16-20 03:41PM  First human trial for coronavirus vaccine begins today: AP Yahoo Finance Video
Mar-13-20 12:40PM  LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day Zacks +16.12%
11:01AM  Coronavirus Drug Development Efforts Pick Up Amid Sell-Off Zacks
Mar-12-20 10:36AM  3 Small Biotechs Provide Coronavirus Drug Development Updates Zacks +11.34%
10:07AM  Company News for Mar 12, 2020 Zacks
09:01AM  Vir (VIR) Looks Good: Stock Adds 12.9% in Session Zacks
08:00AM  Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19 GlobeNewswire
Mar-11-20 08:00AM  Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses GlobeNewswire +12.91%
Mar-10-20 08:25PM  Vir Biotechnology to Present at Barclays Global Healthcare Conference GlobeNewswire -23.31%
Mar-06-20 07:43AM  The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals Zacks
Mar-05-20 09:19AM  Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus Zacks
08:22AM  House Okays $8 Billion Funds to Combat COVID-19: 3 Winners Zacks
Mar-04-20 03:38PM  Coronavirus update: Markets rally, but infections creep closer to 100K amid spike in cases outside China Yahoo Finance +9.59%
08:40AM  Vir Biotech, Alnylam Stitch COVID-19 Therapy Partnership Benzinga
07:37AM  The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies Benzinga
Mar-02-20 09:08AM  Small-Cap Biotech Stocks Soar on Coronavirus Speculation Investopedia
Feb-28-20 02:14PM  Biotech outlook as companies race to develop coronavirus vaccine Yahoo Finance Video -22.76%
10:28AM  Trending ticker: Vir Biotechnology gets coronavirus bounce Yahoo Finance Video
Feb-27-20 04:29PM  Trending Ticker: VIR Surges as Coronavirus fears persist Yahoo Finance Video +72.12%
10:18AM  Trending ticker: Pharma companies seek to help combat COVID-19 Yahoo Finance Video
Feb-25-20 09:16AM  3 Healthcare Stocks Fighting the Coronavirus TipRanks +14.61%
08:30AM  Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19 GlobeNewswire
Feb-24-20 08:47PM  Vir Biotechnology to Present at 40th Annual Cowen Healthcare Conference GlobeNewswire +16.61%
Feb-12-20 08:30AM  Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2 GlobeNewswire
Jan-24-20 05:57PM  Coronavirus Stocks Zacks +17.49%
08:55AM  CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs Zacks
Jan-23-20 10:18AM  3 Biotech Stocks Likely to Gain as Coronavirus Spreads Zacks
07:24AM  The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment Benzinga
Jan-22-20 05:45PM  Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus GlobeNewswire
Jan-13-20 08:00AM  Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-09-20 08:00AM  Sundial and Vir Pharmaceuticals Sign Medical Cannabis Supply Agreement for Australian Chronic Pain Clinical Studies CNW Group
Jan-07-20 05:09PM  Vir Biotechnology to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Nov-19-19 04:15PM  Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-07-19 09:16AM  Goldman Sachs Says These 3 Buy-Rated Stocks Are Primed for Growth TipRanks
Oct-25-19 01:16AM  SoftBank's Vision Fund Writedown Can't Be the Half of It Bloomberg
Oct-11-19 05:01PM  Gates-Backed Vir Biotechnology Flops in Trading Debut Bloomberg
12:48PM  Bill Gates-Backed IPO Is Among 2019s Worst Debuts Bloomberg
Oct-10-19 07:41PM  Vir Biotechnology Announces Pricing of Initial Public Offering GlobeNewswire
04:15PM  BioNTech IPO Falls in Trading Debut as Biotech IPO Wave Ebbs Bloomberg
Oct-09-19 08:53AM  Vir Biotech IPO: What You Need To Know Benzinga
Oct-07-19 07:53AM  IPO Outlook For The Week: Banking And Biotech Benzinga
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.